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Abstract
Background: Prior studies describing the treatment of symptomatic knee osteoarthritis with injections of bone
marrow concentrate have provided encouraging results. The relationship between the cellular dose contained
within the bone marrow concentrate and efficacy of the treatment, however, is unclear. In the present study we
describe clinical outcomes for symptomatic knee osteoarthritis in relation to higher and lower cell concentrations
contained within a bone marrow concentrate treatment protocol.
Methods: Data from an ongoing patient registry was culled to identify 373 patients that received bone marrow
concentrate injections for the treatment of 424 osteoarthritic knee joints. The clinical scales for these patients were
assessed at baseline and then tracked post-procedure at 1, 3, 6 and 12 months, and annually thereafter. Tracked
outcomes included the numeric pain scale; a lower extremity functional questionnaire; an International Knee
Documentation Committee scale; and a subjective improvement rating scale. Using pain and functional outcome
measures, a receiver operating characteristic analysis was used to define an optimal clinical outcome threshold at
which bone marrow nucleated cell count could be divided into either a lower or higher cell count group within a
treatment protocol.
Results: The lower and higher cell count groups were defined using a threshold of 4 × 108 cells. There were 224
and 185 knee joints treated in the lower (≤4 × 108) and higher (>4 × 108) cell count groups respectively. Most joints
were diagnosed with early stage knee osteoarthritis. Both the lower and higher cell count groups demonstrated
significant positive results with the treatment for all of the pain and functional metrics. The higher cell count group
reported lower post treatment numeric pain scale values, in comparison with the lower cell count group (1.6 vs. 3.2;
P < 0.001). No significant differences were detected for the other metrics, however.
Conclusions: Improved function and reduced pain was observed in patients treated with a bone marrow concentrate
protocol regardless of cellular dose; however, patients receiving a higher concentration of cells reported a better pain
outcome in comparison with the lower dose group. These preliminary findings suggest that cell dose may be an
important factor governing clinical outcomes in autologous bone marrow concentrate treatment of knee osteoarthritis.
Further studies using a larger patient population may help elucidate these findings.
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Background
Osteoarthritis of the knee is a common and progressive
joint disorder characterized by gradual deterioration of
the articular cartilage and inflammation of the adjacent
tissues. An estimated 9 million people in the United
States suffer from symptomatic knee osteoarthritis, and
depending on disease severity, management ranges from
conservative treatment to surgical intervention, includ-
ing total knee replacement (TKR) [1]. In recent years the
number and cost of TKR has increased dramatically;
from 305,000 procedures costing an average of $25,500
per surgery in 2001 to 610,000 procedures costing an
average of $52,000 per surgery in 2012 [2]. TKR is asso-
ciated with significant complications, including deep
vein thrombosis and infection, as well as post-surgical
joint stiffness and muscle atrophy [3, 4]. Other lower
risk surgical procedures are available as stopgap mea-
sures prior to TKR, such as arthroscopic meniscectomy,
but such procedures are demonstrably lacking in long-
term efficacy when compared with sham control proce-
dures [5].
Non-surgical approaches to treating knee osteoarth-
ritis, such as percutaneous injection of biological sub-
stances (e.g. hyaluronic acid and platelet-rich plasma
(PRP), and Bone marrow derived nucleated cells
(BMNCs)), represent a lower cost and lower risk alter-
native to surgery [6]. Clinical studies of intra-articular
injection of PRP or BMNCs into the knee have demon-
strated reduction of pain and improved function [7, 8].
In humans, nucleated cells are isolated from the aspir-
ate of bone marrow that is typically harvested from the
superior iliac crest of the pelvis via trocar [9]. The com-
position of these nucleated cells is diverse including
Mesenchymal Stem Cells (MSCs), Hematopoetic Stem
Cells (HSCs), Monocyte Precursor cells, Macrophages, T
cells, B cells, Dendritic Antigen Presenting Cells, Natural
Killer Cells and Neutrophils [10–12]. The action of these
cells, acting both in isolation and symbiotically, once in-
troduced into arthritic joints may help improve pain and
function by replenishing damaged joint structures and
providing a mediation of catabolic immune response,
thus alleviating the symptoms and progression of the
disease [12, 13].
MSCs are multipotent with the capacity to differenti-
ate into various cell types from a mesodermal origin
including cartilage, ligament, tendon, bone and fat [13].
Prior animal studies have demonstrated cartilage healing
after joint osteoarthritis treatment with high dose
expanded MSCs [14–16]; however, Bone Marrow Con-
centrate (BMC) contains only a fraction of the MSCs
described in these studies [17]. Interestingly, other
studies have demonstrated comparable results with
direct application of BMNCs without the isolation and
expansion of MSCs [10]. These observations raise
numerous questions including to what extent the other
nucleated cells in the bone marrow affect tissue healing
and whether there is an optimal BMC cell dose for the
most efficacious treatment of joint osteoarthritis.
BMC protocols have been employed throughout the
growing field of Regenerative Medicine in the treatment
of osteoarthritis [8, 13]. These protocols often contain
PRP or Platelet lysate (PL), which enhance both bone
marrow and adipocyte derived MSCs proliferation when
used as a culture medium in vitro [18, 19]. Laden with
growth factors [13], which have been show to influence
MSC differentiation toward chondrocytes [19, 20], PRP
and PL increase the activity of MSCs.
There is significant variability in MSC content of the
bone marrow from person to person [21], hence provid-
ing the correct autologous dose to a joint could be im-
portant. Traditionally colony forming units have been
used as a proxy for MSC dose [22, 23], but this tech-
nique can’t be used in real time to adjust the amounts
injected at the bedside as it requires several days of cul-
ture for colony formation. Alternatively, flow cytometry
could be used, but this technology is expensive and takes
a dedicated lab staff to run, and is thus impractical for
office based, clinical use [24]. Nucleated cell count may
be a solution for office based use as the count is easy to
obtain at the bedside and several studies show that it is
a reasonable proxy for MSC dose [25, 26]. In addition,
having nucleated cell count data readily available before
cells are re-injected into a joint could allow for adjust-
ments of the dose.
In the present observational study using registry data,
we examine the effectiveness of using a specific lower
and higher BMNC dose injection protocol for the treat-
ment of knee osteoarthritis. We also analyze the clinical
outcome differences between the two doses.
Methods
Setting and participants
Outcomes data for this study was derived from a previ-
ously reported treatment registry of patients receiving
autologous MSCs, BMC, or PRP for the treatment of
joint disorders including among others, knee, hip, and
shoulder joints [25, 27–30]. The registry protocol was
approved by a Institutional Review Board (HHS OHRP
#IRB00002637). All subjects (or their guardians if they
were under 18 years old) were required to undergo an
informed consent process and sign an informed con-
sent form before they enter the registry. In the current
study, patients presenting to one clinic with symptom-
atic knee osteoarthritis, as determined by Magnetic
Resonance Imaging (MRI), and knee pain complaints
with decreased function were included for analysis.
Knee osteoarthritis on MRI was defined as any abnor-
malities of the cartilage, bone, or meniscus for example:
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chondral or osteochondral defects, chondral loss, me-
niscus tears, bone marrow lesions, joint space narrow-
ing, bone marrow lesions, or bone spurring. All MRI
images were read, and severity grades were determined
by treating physicians. All patients who were treated
with BMC injections, combined with PRP and PL, were
included in the study.
Patients enrolled in the treatment registry were
prospectively followed using an electronic system,
ClinCapture software (Clinovo Clinical Data Solutions,
Sunnyvale, California) that generates an automated,
post-treatment, questionnaire for evaluation at 1, 3, 6
and 12 months, and annually thereafter. Registry staff
compiled all data, as well as contacted patients that
failed to respond to the electronic survey.
Procedure description
A detailed description of BMC aspiration and injection
procedures has been previously published [31]. Briefly,
two weeks prior to undergoing BMC injection, patients
were restricted from use of corticosteroids and non-
steroidal anti-inflammatory drugs (NSAIDs) as this
reduces healing. On the day of the procedure, approxi-
mately 10–15 cc of whole bone marrow aspirate was
harvested from 6 to 8 bone sites (approximately 3–4 on
each side) of the patients’ Posterior Superior Iliac Crest.
Under sterile conditions, the whole bone marrow aspir-
ate was sequentially centrifuged, and resultant nucle-
ated cells contained within were isolated for injection.
Concomitantly, patient-derived heparinized venous blood
was used to isolate PRP, and prepare PL by freeze-thawing
the PRP. Using ultrasound or fluoroscopy to guide needle
placement, a nucleated cell preparation of varying
dose, contained within varying volume, and standard-
ized volumes of PRP and PL were delivered to both the
intra-articular space as well as painful or damaged
structures of the knee. For example, if a meniscus tear
was detected upon MRI or ultrasound examination,
then in addition to the intra-articular space, the menis-
cus tear area was also injected with the nucleated cell
preparation.
Post-operatively, patients with one compartment dom-
inant disease (i.e. a single site within the knee joint) were
provided with activity instructions and fitted with an off-
loader brace that was to be worn for duration of 6 weeks
for all weight bearing activity. Patients with patella-
femoral compartment disease were fitted with a patella
brace and instructed to avoid bearing full weight on the
treated extremity for several days, then resume full
weight bearing as soon as feasible. Full activity was grad-
ually implemented over a 6-week period. Although pa-
tients were encouraged to undergo physical therapy, it
was not required nor controlled.
Nucleated cell dose
The predictor of interest in this study was the total nucle-
ated cell count contained in the bone marrow aspirate.
The number of nucleated cells in each patient sample was
manually counted under a microscope (National Optical,
Schertz, TX) using a hemocytometer (Reichert Bright-
Line, Hausser Scientific, Horsham, PA). Prior to counting,
red blood cells were lysed by diluting 5 μL of sample in
995 μL of sterile, distilled water (Life Technologies, Grand
Island, NY). Each sample was counted four times and the
average calculated. The total nucleated cell count for in-
jection was determined by multiplying the dilution factor,
the volume of the hemocytometer, and the final volume of
the sample.
Covariates
An examination of potentially confounding variables in-
cluded: age, gender, BMI, severity of disease, and follow-
up time in months. The baseline severity of osteoarth-
ritis, as well as candidacy for the procedure, was graded
by the treating physician using the Kellgren-Lawrence
(KL) scale, where KL1 represented a “Good” candidacy
grade, KL2 represented a “Fair” grade, and KL3 and 4
signified a “Poor” grade [32]. These categories were
based on the imaging-determined disease severity [33].
This included the use of MRIs and AP standing radiog-
raphy. BMI and follow-up time in months were exam-
ined as continuous numeric variables.
Outcomes of interest
In this study, four clinical scales were used to measure
outcomes of pain or functional improvement. The
follow-up duration for each scale was measured as a
score reported by the patient beginning from the date
of the procedure (i.e. BMC injection) to the date of
the last follow-up.
The NPS was used to assess knee pain based on a one-
item questionnaire that assesses patients’ physical pain in
the affected area using an eleven scoring levels ranging
from 0 (no pain) to 10 (most severe pain) [34]. The LEFS
consists of a 20 item measure of daily activities and func-
tion based on a five-point Likert scale [35], where diffi-
culty levels for each item are classified into: extreme
difficulty or inability to perform activity (0 point), quite a
bit of difficulty (1 point), moderate difficulty (2 points), a
little bit of difficulty (3 points), and no difficulty (4 points).
The total LEFS score is the sum of points for the twenty
items and ranges from 0 (i.e. minimum functional activity)
to 80 points (i.e. maximum functional activity). The Inter-
national Knee Documentation Committee scale (IKDC) is
another subjective questionnaire consisting of 18 items
that measure knee symptoms, function and sport activities
[36]. The total IKDC score ranges from 0 to 100, with
higher scores reflecting a better condition. The IKDC
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form includes three main sections: symptom, sport activ-
ities, and function. The three sections are combined in
one total score. The subjective percentage improvement
rating scale was based on the following question: “Com-
pared to your condition prior to the procedure, what
percent difference have you seen in your condition?” The
patients’ response ranged from −100 % (denoting “worst
condition”) to 100 % (indicating “best condition”). A score
of zero would indicate no change.
Statistical analysis
A receiver operating characteristics (ROC) curve analysis
was used to determine the optimal threshold for dichot-
omizing cell counts into higher and lower cell count
groups. Using a composite variable based on the NPS
and LEFS (see Outcomes of Interest), a ROC curve ana-
lysis identified the level at which sensitivity and specifi-
city for composite pain and functional improvement was
maximized. To avoid having two different cut-points for
the cell count, a composite variable of functional im-
provement and pain was chosen for the analysis rather
than separately evaluating pain and functional improve-
ment. Any improvement to the composite variable was
defined as achieving the minimum important differences
in both the NPS and LEFS, where a minimum important
difference was indicated by a 9-point increase on the
LEFS and a 2-point decrease on the NPS [34, 35]. A lack
of improvement was defined as a failure to achieve any
of these changes.
Mean and standard deviation of the baseline and
follow-up scores are described, as well as the differences
between these two scores. Intra-group changes from the
baseline were analyzed using the signed rank test. An
analysis of covariance (ANCOVA) was used to estimate
the adjusted means, controlling for the associated base-
line score and potential confounding factors. The same
multivariate analysis was conducted on the four out-
come (dependent) variables including: NPS, LEFS, IKDC
and subjective improvement rating scale. ANCOVA
models were tested for the homogeneity of variance,
homogeneity of regression, and normal distribution of
residuals. Homogeneity of variances was tested using
Levene’s tests, and homogeneity of regression was tested
by introducing interaction terms to the models and test-
ing their significance. Models’ residuals were plotted
using histograms and Q-Q plots, and scatter plots for re-
sidual and predicted values were also created. Plots were
examined for normality, presence of outliers, or unusual
patterns. Spearman correlation was also used to test the
correlation between cell doses as a continuous variable
with changes in clinical scales’ scores.
An analysis was also performed to assess the differ-
ences in baseline characteristics between patients who
responded to the follow-up surveys and those who did
not. This analysis included only procedures that had
available data for each respective clinical scale. Wilcoxon
rank sum, chi square, or Fisher exact tests were used
when appropriate. Data were analyzed using SAS 9.4
software (SAS Institute Inc. 2014: Cary, NC). Statistical
significance was considered at p-value ≤ 0.05. Post-hoc
power analysis was performed using G*Power 3.1
software.
Results
Between the periods of August 2010 and February 2014,
a total of 373 patients received treatment in 424 knee
joints. Cell count information was available for 409 of
the procedures. Optimal sensitivity and specificity for
pain and functional improvement was estimated via
ROC at 4 × 108 cells, and served as the value to discrim-
inate between the higher and lower cell count groups
(Fig. 1). There were 185 procedures (n = 170 patients) in
the higher cell count group (>4 × 108 cells), and 224 pro-
cedures (n = 188 patients) in the lower cell count group
(≤4 × 108 cells). Based on the radiological data, 55.6 and
59.4 % of the lower and higher cell count groups had
early stage knee osteoarthritis (KL grade 1) (Table 1).
The distribution of cell counts is presented in Fig. 2, and
baseline characteristics of the higher and lower cell
count groups are reported in Table 1.
The total number of participants responding to the
NPS, LEFS and IKDC questionnaires was 116, 94, and
47, respectively; these frequencies represent subjects
who had available baseline and follow-up data for the re-
spective clinical scale. There were no significant differ-
ences between the responders and non-responders to
questionnaires with regard to demographics or baseline
metrics. A reduction in pain following treatment was
statistically significant in both treatment groups, as the
Fig. 1 Sensitivity and specificity for composite pain and functional
improvement as predicted by the nucleated cell count and
examined by the receiver operating characteristics curve analysis
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NPS decreased by 1.5 and 0.9 in the higher and lower
cell count groups, respectively (P < 0.001 and P = 0.006).
There were positive changes in both the LEFS and IKDC
scales in both groups as well; the LEFS scale improved
by 8.9 and 4.8 (P = 0.002 and 0.001), and the IKDC im-
proved by 14.2 and 19.7 (P < 0.001 and P = 0.004), for
the higher and lower cell count groups, respectively.
After adjusting for potential confounding factors (see
Tables 2, 3), the outcomes for the higher and lower cell
count groups were compared. A difference in the NPS
means between the two cell count groups was statisti-
cally significant (higher cell count group mean = 1.6, ver-
sus lower cell count group mean = 3.2; P < 0.001). In
contrast, a comparison between the adjusted means for
LEFS and IKDC scores indicated no significant differ-
ences between the higher and lower cell count groups.
Spearman correlation test showed that only changes in
NPS scores were correlated with cell dose as a continu-
ous variable with a borderline statistical significance
(correlation coefficient = −0.13, P = 0.081). Other clinical
scales did not show significant correlation with cell dose.
Discussion
Consistent with the previously published results from
our group and others, significant improvement of pain
and function was observed in osteoarthritis knee joints
following injection with BMC at both higher and lower
doses of nucleated cells [8, 37]. In both groups, most
knee joints were diagnosed with early-stage knee osteo-
arthritis. Although a higher cell count dose was associ-
ated with a greater reduction in pain, there were no
significant differences in functional improvement includ-
ing the LEFS and IKDC, and the subjective improvement
rating scale following injection with either a higher or
lower cell count.
Although absolute difference in pain outcomes be-
tween higher and lower doses was less than two points,
the minimum important difference defined in the litera-
ture; the NPS score in the higher dose group was 50 %
lower than that in the lower dose group, a difference
which is considered clinically significant [38] especially
given the fact that the comparison is made between two
low means; therefore we do not expect to see a high ab-
solute difference in scores despite the highly significant
difference as a percentage.
Prior studies of cell dose and therapeutic efficacy of
the BMC injectate have been inconclusive. In animal
studies, intra-articular injection of either BMC (lower
MSC content) or culture-expanded MSCs (higher MSC
content) facilitated regeneration of damaged cartilage;
however, neither approach showed any superiority in
therapeutic efficacy [39]. Clinical studies in humans have
demonstrated mixed results, with one study indicating
the superiority of higher concentrations of MSCs at re-
pair of cartilage and meniscus injury [40], and another
study indicating greater efficacy at lower cell concentra-
tions of culture-expanded allogeneic cells [41]. The
Table 1 Baseline characteristics and the statistical significance
of the differences between the lower and higher cell count
groups (NC = nucleated cells, SD = standard deviation,
KL = Kellgren-Lawrence)
NC≤ 4 × 108 cells NC > 4 × 108 cells P-value
N Mean SD N Mean SD
Age 224 54.5 12.8 185 50.2 15.6 .003
BMI 207 25.4 3.8 168 25.9 3.9 .241
NC Count (X108) 2.2 2.7 83.6 185 6.8 2.8 <.001
Gender 224 185 .001
Male 143 63.8 % 140 75.7 %
Female 81 36.2 % 45 24.3 %
Severity grade 160 128 .801
KL1 89 55.6 % 76 59.4 %
KL2 48 30 % 36 28.1 %
KL3-4 23 14.4 % 16 12.5 %
Fig. 2 Nucleated cell count of the study population. Lower nucleated cell count group was categorized as≤ 4 × 108 cells; whereas in the higher
cell count group, there were > 4 × 108 nucleated cells
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findings from the latter study may be explained by a
greater host immune response resulting from the
higher-doses of allogeneic cells [26].
Previous work investigating MSC concentration in the
reduction of discogenic low back pain, revealed similar
findings with patients receiving higher cell concentration
intra-discal injections reporting a statistically significant
greater reduction in pain compared to lower cell con-
centrations [23]. The findings of the present study are
unique; prior studies have described the use of BMC for
treatment of symptomatic osteoarthritis, but there are
none that have examined a cell dose response, or identi-
fied an optimal threshold count of nucleated cells for
maximizing clinical outcome [31].
Conceptually, it makes sense that a higher BMNC
count equates to better pain relief than a lower cell
count. Nucleated cell count is a proxy for the total num-
ber of MSCs, and MSCs are the cells that contribute to
regeneration of intra-articular cartilage [25, 42]. Unlike
studies that have focused on culture expanded MSCs,
the number of these cells in BMC is much smaller [24].
Hence, dose may be more critical in some patients with
poor MSC counts in bone marrow, which is common in
older patients [21]. Additionally, BMC constituents in-
cluding hematopoietic stem cells, T-lymphocytes, B-
lymphocytes, monocytes, macrophages, epithelial pro-
genitor cells and platelets, are all capable of producing
growth factors and cytokines that together may support
a microenvironment that promotes proliferation and
functional differentiation of MSCs as well as cartilage
repair [43]. For example, co-culture of MSCs with
Monocytes has been shown to increase chondrogenic
differentiation capacity [12]. Finally, MSCs have been
shown to reduce pain in animal models by the release of
TGF-beta [44].
It is important to note that the observed treatment’s
effect may be attributed to the platelet component of
Table 2 Baseline and follow-up means of the clinical scales, significance of intra-group changes and follow-up duration in months
(NC = nucleated cells, SD = standard deviation, LEFS = lower extremity functional scale, NPS = numeric pain scale, IKDC = international
knee documentation committee scale, P-values are for intra-group changes, improvement rating = percentage improvement
rating scale)
NC ≤ 4 × 108 cells NC > 4 × 108 cells
Variable N Mean SD P-value N Mean SD P-value
NPS
Baseline 67 4 2 49 3.1 1.8
Follow-up 67 3.1 2.5 49 1.7 2.1
Change 67 −0.9 2.7 .006 49 −1.5 2.5 <.001
Follow-up duration 67 10.6 8.5 49 11 8.6
LEFS
Baseline 57 48.8 13.9 37 50.7 13.9
Follow-up 57 53.5 18.7 37 59.6 17
Change 57 4.8 16.7 .001 37 8.9 15.3 .002
Follow-up duration 57 8.5 6.5 37 8.5 6.1
IKDC
Baseline 25 45 16.1 22 55.9 16.6
Follow-up 25 64.7 18 22 70.1 16.7
Change 25 19.7 15.5 <.001 22 14.2 14.7 .004
Follow-up duration 25 6.3 7.5 22 5.7 3.5
Improvement rating
Follow-up 137 47 37.1 103 48.3 41.3
Follow-up duration 137 14.8 11.6 103 13.4 10.7
Table 3 Means of the last follow-up scores of clinical scales ad-
justed for baseline score of the respective scale, follow-up time,
age, BMI, gender, and severity grade (NC = nucleated cells,
SE = standard error, LEFS = lower extremity functional scale,
NPS = numeric pain scale, IKDC = international knee docu-
mentation committee scale, improvement rating = percentage
improvement rating scale)
NC≤ 4 × 108 cells NC > 4 × 108 cells
N Mean SE N Mean SE P-value
NPS 67 3.2 0.3 49 1.6 0.3 <.001
LEFS 57 53.4 2.4 37 58.7 2.7 .114
IKDC 25 68.3 3.7 22 68.4 3.9 .989
Improvement rating 137 46.4 3.7 103 50.9 4.3 .372
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injections; PRP and PL have been shown in numerous
studies to improve the symptoms associated with
mild-moderate knee osteoarthritis [45–47]. However,
the clinical efficacy of PRP therapy is transient, and
relief from pain and function improvement declines
to baseline between 6 and 24 months after treatment
[48, 49]. Further, the efficacy of PRP therapy is lim-
ited in moderate and severe osteoarthritis, versus mild
osteoarthritis [7, 50, 51]. Finally, the significant differ-
ence in pain score associated with the higher nucle-
ated cell group in this study reveals that varying MSC
dose, within a standardized protocol of platelet injec-
tions, has an impact on treatment outcome.
Limitations of the present study are typical of registry
studies; there was no placebo control group, and there
was no randomization of the patients into the lower and
higher cell dose groups. As a result it is possible that un-
controlled for confounding factors or even a placebo ef-
fect may account for the results. It is unlikely that the
positive results observed for both cell count groups were
due to response bias; the analysis of the non-responders
indicated no significant differences with regard to age,
gender, weight, or baseline severity in comparison with
the responders. Also the lack of significance of the dif-
ferences in the functional outcome scales may be due to
limited statistical power. Another limitation of this study
is that the ROC analysis and ANCOVA models were
performed on data subsets obtained from the same
population. ROC analysis was performed on subjects
who had available baseline and follow-up scores for both
LEFS and NPS scales. ANCOVA models included sub-
jects who had available data for all covariates, in addition
to the baseline and follow-up scores of the respective
outcome scale. Therefore, future research on different
populations is needed to confirm our study’s findings.
Sufficiently powered randomized placebo-controlled tri-
als are needed to validate and expand on these prelimin-
ary results.
Conclusion
Improved function and reduced pain was observed in
patients treated with BMC injectate regardless of cellular
dose; however, patients receiving a higher concentration
of cells reported a better pain outcome in comparison
with the lower dose group. These findings indicate that
cell dose may be a factor governing clinical outcomes in
autologous BMC treatment of knee osteoarthritis. Fur-
ther studies using randomized and placebo-controlled
design are needed.
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